XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Our disaggregated revenues were as follows (in thousands):
Three Months Ended
 September 30,		Nine Months Ended
September 30,
2023202220232022
Royalties$114,433 $99,551 $325,813 $254,496 
Product sales, net
  Sales of bulk rHuPH2037,001 19,259 86,203 60,764 
Sale of proprietary products31,511 24,180 91,765 44,559 
Sale of device partnered products18,057 17,988 43,284 24,544 
Total product sales, net$86,569 $61,427 $221,252 $129,867 
Revenues under collaborative agreements
  Upfront license and target nomination fees— — — 30,000 
  Event-based development and regulatory milestone and other fees13,000 44,000 46,000 59,000 
  Device licensing and development revenue2,031 3,998 6,149 5,257 
Total revenues under collaborative agreements$15,031 $47,998 $52,149 $94,257 
Total revenues$216,033 $208,976 $599,214 $478,620 
During the three months ended September 30, 2023, we recognized revenue related to licenses granted to partners in prior periods in the amount of $127.4 million. This amount represents royalties earned in the current period in addition to $13.0 million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $0.1 million during the three months ended September 30, 2023 that had been included in deferred revenues in our condensed consolidated balance sheets as of December 31, 2022.
During the nine months ended September 30, 2023, we recognized revenue related to licenses granted to partners in prior periods in the amount of $371.8 million. This amount represents royalties earned in the current period in addition to $46.0 million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $3.2 million during the nine months ended September 30, 2023 that had been included in deferred revenues in our condensed consolidated balance sheets as of December 31, 2022.
Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands):
September 30, 2023December 31, 2022
Accounts receivable, net$213,987 $186,970 
Other contract assets3,338 44,102 
Deferred revenues2,920 5,499 
As of September 30, 2023, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $86.1 million, of which $83.2 million relates to unfulfilled product purchase orders and $2.9 million has been collected and is reported as deferred revenues in our condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2024. Of the total deferred revenues of $2.9 million, $0.7 million is expected to be used by our customers within the next 12 months.
We recognized contract assets of $3.3 million as of September 30, 2023, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.